Skip to main content

Published locations for HR+/HER2− metastatic BC: Greater survival benefit observed with ET+CDK4/6 inhibitor vs ET

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. HR+/HER2− metastatic BC: Greater survival benefit observed with ET+CDK4/6 inhibitor vs ET

User login

  • Reset your password
  • /content/hr/her2-metastatic-bc-greater-survival-benefit-observed-etcdk4/6-inhibitor-vs-et
  • /hematology-oncology/article/261955/breast-cancer/hr/her2-metastatic-bc-greater-survival-benefit